Regent Investment Management LLC increased its position in Johnson & Johnson (NYSE:JNJ) by 0.3% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 50,931 shares of the company’s stock after buying an additional 160 shares during the period. Johnson & Johnson accounts for about 2.3% of Regent Investment Management LLC’s investment portfolio, making the stock its 7th biggest position. Regent Investment Management LLC’s holdings in Johnson & Johnson were worth $7,094,000 at the end of the most recent reporting period.
Other large investors have also recently bought and sold shares of the company. OLD National Bancorp IN raised its position in Johnson & Johnson by 0.8% during the second quarter. OLD National Bancorp IN now owns 150,881 shares of the company’s stock valued at $21,015,000 after purchasing an additional 1,229 shares during the period. Stokes Capital Advisors LLC raised its position in Johnson & Johnson by 2.4% during the second quarter. Stokes Capital Advisors LLC now owns 22,753 shares of the company’s stock valued at $3,169,000 after purchasing an additional 525 shares during the period. JGP Wealth Management LLC raised its position in Johnson & Johnson by 3.2% during the second quarter. JGP Wealth Management LLC now owns 37,658 shares of the company’s stock valued at $5,245,000 after purchasing an additional 1,170 shares during the period. Capital Asset Advisory Services LLC raised its position in Johnson & Johnson by 6.1% during the second quarter. Capital Asset Advisory Services LLC now owns 2,360 shares of the company’s stock valued at $329,000 after purchasing an additional 135 shares during the period. Finally, Liberty Capital Management Inc. raised its position in Johnson & Johnson by 13.2% during the second quarter. Liberty Capital Management Inc. now owns 7,948 shares of the company’s stock valued at $1,107,000 after purchasing an additional 925 shares during the period. Institutional investors own 66.78% of the company’s stock.
Shares of NYSE JNJ traded down $0.15 during midday trading on Friday, hitting $130.14. The company’s stock had a trading volume of 1,545,448 shares, compared to its average volume of 7,045,821. The company has a current ratio of 1.33, a quick ratio of 1.13 and a debt-to-equity ratio of 0.46. The business’s 50 day moving average price is $136.91. Johnson & Johnson has a 12-month low of $121.00 and a 12-month high of $148.99. The firm has a market capitalization of $348.58 billion, a price-to-earnings ratio of 15.91, a P/E/G ratio of 2.23 and a beta of 0.70.
The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 10th. Stockholders of record on Tuesday, August 27th will be issued a $0.95 dividend. The ex-dividend date is Monday, August 26th. This represents a $3.80 annualized dividend and a dividend yield of 2.92%. Johnson & Johnson’s payout ratio is 46.45%.
In other Johnson & Johnson news, Director Marillyn A. Hewson purchased 3,000 shares of Johnson & Johnson stock in a transaction dated Tuesday, June 11th. The shares were purchased at an average cost of $139.68 per share, for a total transaction of $419,040.00. Following the completion of the acquisition, the director now owns 3,000 shares in the company, valued at approximately $419,040. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. Corporate insiders own 0.23% of the company’s stock.
A number of brokerages have issued reports on JNJ. Raymond James decreased their price objective on Johnson & Johnson from $147.00 to $146.00 and set an “outperform” rating on the stock in a research report on Wednesday, July 17th. Credit Suisse Group set a $156.00 price objective on Johnson & Johnson and gave the company a “buy” rating in a research report on Thursday, July 18th. Bank of America restated a “hold” rating and set a $150.00 price objective on shares of Johnson & Johnson in a research report on Tuesday, July 16th. Wells Fargo & Co restated an “outperform” rating and set a $157.00 price objective (up from $152.00) on shares of Johnson & Johnson in a research report on Monday, May 6th. Finally, Zacks Investment Research downgraded Johnson & Johnson from a “buy” rating to a “hold” rating and set a $139.00 price objective on the stock. in a research report on Thursday, July 18th. Five analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $148.56.
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Featured Story: What is the G-20?
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.